Pure Global
NCT05548803

COVID-19 Citizen Science Expansion Project

Comparing Patient-reported Impact of COVID-19 Shelter-in-place Policies and Access to Containment and Mitigation Strategies, Overall and in Vulnerable Populations
University of California, San Francisco·ClinicalTrials.govEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Covid19
Study type
Observational
Sponsor & location
Primary sponsor
University of California, San Francisco
Location
Sacramento,San Francisco,Downers Grove,New Orleans,Bronx,New York,New York,Dallas,Salt Lake City, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 24, 2020
End date
Jun 01, 2023
Enrollment
150000 participants
Primary outcome

Difficulty paying for the very basics,Time-to-testing if symptomatic

Summary

COVID-19 Citizen Science (CCS), launched in March 2020, supports collaborative research on
 symptoms, risk factors, surveillance, biomarkers and testing for COVID-19 using the Eureka
 Research Platform. CCS maintains IRB approval with UCSF's IRB (UCSF IRB# 17-21879).
 
 This CCS Expansion Project, which is funded jointly by the National Institutes of Health
 (NIH), the Patient-Centered Outcomes Research Institute (PCORI), and the Bill and Melinda
 Gates Foundation, will invite patients at health systems across the US to contribute their
 health records data and then join the established CCS study, allows for linked analysis of
 CCS data and health records data, and provides the scientific rationale and plan for the
 project.

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05548803
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05548803 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, San Francisco and is currently Enrolling by invitation. The study focuses on Covid19. Target enrollment is 150000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.